Freda Lewis-Hall

Catalio Capital thesis

Home Strategies Overview Private Equity Structured Opportunities Public Equities Co-Investments Portfolio Team News Investor Login SEI Login MSFS Login Investor login SEI Login MSFS Login [Portfolio] Affini-T Visit website Affini-T is a preclinical-stage company developing T-cell therapeutics founded by Catalio Venture Partner and immunotherapy pioneer Dr. Phil Greenberg. Although cell therapies have transformed the care of some liquid tumors, they have shown little to no efficacy in solid tumors due to key issues in T-cell biology and a lack of viable tumor-specific targets. To address these

Sector and stage focus

• Seed: Pharmaceuticals, BioTech, Consumer Health, Health IT, Digital Health, Health & Hospital Services
• Series A: Consumer Health, Pharmaceuticals, Health IT, BioTech, Health & Hospital Services, Digital Health
• general: New York City

Is Freda Lewis-Hall a fit for your round?

Upload your pitch deck and see whether Freda Lewis-Hall appears in your top 20 matches.